A comparison of <scp>DNA</scp> sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
Atara Posner(The University of Melbourne), Richard W. Tothill(The University of Melbourne), Dariush Etemadamoghadam(Peter MacCallum Cancer Centre), Tharani Sivakumaran(The University of Melbourne), Andrew Fellowes(Peter MacCallum Cancer Centre), Gavin Wright(The University of Melbourne), Niko Thio(Peter MacCallum Cancer Centre), Anna DeFazio(The University of Sydney), Samantha Webb(Peter MacCallum Cancer Centre), Andrew Pattison(University of Melbourne), David D.L. Bowtell(The University of Melbourne), Anthony J. Gill(The University of Sydney), Ian Collins(St. James's Hospital), Mark Warren(Bendigo Health), Joshy George(Jackson Laboratory), Huiling Xu(Shandong Agricultural University), Benjamin Solomon(Peter MacCallum Cancer Centre), Penelope Schofield(Swinburne University of Technology), Colin S. Wood(University of Glasgow), Nicholas Wilcken(Westmead Hospital), Rodney J. Hicks(Flinders Medical Centre), Shiva Balachander(University of Melbourne), Linda Mileshkin(Peter MacCallum Cancer Centre), Christos S. Karapetis(Clínica Alemana), Bo Gao(Sun Yat-sen University), Narayan Karanth(Cancer Council Northern Territory), Christopher Steer(Albury Wodonga Health), Scott Williams(The University of Sydney), Krista Fisher(The University of Melbourne), Stephen B. Fox(Peter MacCallum Cancer Centre), Alex Boussioutas(The Royal Melbourne Hospital), Owen W.J. Prall(The University of Melbourne), Madhu Singh(Barwon Health), Gary Richardson(Cabrini Hospital)
Cited by 27
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k